This article is more than 5 years old. Information may no longer be current.

Intraorbital corticosteroids show efficacy for treating idiopathic orbital inflammation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

With proper patient selection, injecting corticosteroids intraorbitally may be effective as a first-line treatment for idiopathic orbital inflammation, according to a prospective study by researchers in Israel and Australia.

Igal Leibovitch, MD, and colleagues evaluated the local and systemic complications after intraorbitally injecting 20 mg/mL to 40 mg/mL of triamcinolone acetonide in 10 patients with confirmed idiopathic orbital inflammation and an anterior orbital mass.

Investigators repeated the injections every 4 weeks if patients did not achieve complete resolution.

The researchers reported finding an anterior orbital mass in four patients and dacryoadenitis in six patients.

At 9.8 months mean follow-up, substantial improvement was noted in one patient and complete resolution was noted in eight patients, according to the study, published in the December issue of Archives of Ophthalmology.